Modern medicine has achieved extraordinary success in treating acute disease. Yet when it comes to chronic degenerative conditions, the diseases that dominate healthcare spending and disability in aging populations, our healthcare system remains fundamentally reactive.
Patients typically enter the medical system only after symptoms become severe enough to demand treatment. By that point, disease processes may have been progressing silently for years or even decades. Physicians are then left with a limited set of tools: manage symptoms, slow deterioration, or repair damage once it has already occurred.
This reactive model has shaped clinical practice, reimbursement systems, and regulatory frameworks for decades. But it is increasingly misaligned with what modern biology is teaching us about chronic disease. Many of the most prevalent conditions, including osteoarthritis, autoimmune disease, and metabolic disorders, develop through long periods of progressive biological dysfunction driven by inflammation, immune dysregulation, and gradual tissue degeneration.
By the time these diseases become clinically apparent, substantial damage may already be irreversible.
Regenerative medicine offers the potential to fundamentally change this trajectory. Advances in cell therapy, biologically active scaffolds, and tissue engineering are beginning to create therapeutic approaches that target the biological drivers of degeneration rather than simply treating downstream symptoms. But realizing this potential will require more than scientific innovation. It will require a shift in how healthcare systems think about disease intervention.
Regenerative therapies are unlikely to reach their full impact if they are introduced only after disease has advanced to late stages. Instead, these technologies are best suited to earlier intervention, i.e., when inflammatory signaling, immune dysregulation, and tissue degeneration can still be modulated before structural damage becomes permanent.
From the perspective of companies actively developing regenerative therapies, the challenge is not simply proving clinical efficacy; it is ensuring that healthcare systems are prepared to deploy these therapies at the stage of disease where they can deliver the greatest benefit.
In other words, regenerative medicine is not simply a new class of therapies. It represents an opportunity to move healthcare from a model centered on reactive treatment toward one focused on proactive disease modification.
The promise of regenerative medicine
Regenerative medicine encompasses a broad set of therapeutic approaches, including cell therapies, biologically active scaffolds, and gene-based technologies, designed to repair tissue or alter the biological processes that drive disease.
Among the most widely studied regenerative therapies are treatments derived from mesenchymal stromal/stem cells (MSCs). Rather than functioning primarily through direct tissue replacement, MSCs exert many of their therapeutic effects through paracrine signaling. These cells secrete cytokines, growth factors, extracellular vesicles, and other signaling molecules that influence immune activity and tissue repair mechanisms.1,2
These signaling pathways can affect several biological processes relevant to degenerative disease, including:
- Reduction of pro-inflammatory cytokine activity
- Modulation of immune cell signaling
- Alteration of catabolic and anabolic pathways in tissues
- Support of endogenous tissue repair mechanisms
Because these biological pathways operate early in many degenerative diseases, regenerative therapies may be most effective during the early to moderate stages of disease progression, when structural damage has not yet progressed beyond the body’s ability to maintain or restore tissue function.
This creates a therapeutic window in which regenerative interventions may slow degeneration, stabilize tissue function, or delay the need for invasive procedures—a therapeutic concept often described as disease modification.
Targeting inflammation-driven degenerative disease
Many chronic degenerative diseases share a common biological driver: persistent inflammation that gradually disrupts tissue homeostasis.
Osteoarthritis (OA) illustrates this process clearly. Once viewed primarily as a mechanical “wear-and-tear” condition, OA is now recognized as a complex disease involving inflammatory signaling pathways, synovial activation, and progressive cartilage degeneration.3
Regenerative therapies targeting the inflammatory microenvironment of the joint may help alter these pathways. Intra-articular MSC therapies, for example, are being studied for their ability to reduce inflammatory signaling and influence the balance between catabolic processes that degrade cartilage and anabolic processes that support tissue maintenance.
Several clinical studies have begun to demonstrate the therapeutic potential of MSC-based therapies in degenerative joint disease. In a multicenter randomized clinical trial comparing implantation of MSCs versus a hyaluronate gel with a microfracture procedure for large cartilage defects of the knee, patients receiving the MSC-based therapy showed significantly greater improvements in pain and functional outcomes over a five-year follow-up period.4
These findings illustrate how regenerative therapies may help stabilize degenerative processes before structural damage becomes advanced enough to require joint replacement.
A growing number of clinical programs are now exploring regenerative cell therapies for focal cartilage lesions and early OA—conditions that often precede the development of advanced joint degeneration. In these settings, biologic therapies designed to modulate inflammation and support cartilage repair may help stabilize the joint environment before extensive structural damage occurs.
If such approaches prove capable of delaying or preventing the need for joint replacement surgery, they could significantly alter the treatment paradigm for one of the most common causes of disability in aging populations.
At the same time, degenerative joint disease is multifactorial. In cases where OA results primarily from biomechanical abnormalities, such as chronic joint instability or abnormal loading patterns, those structural issues may need to be addressed before regenerative therapies can provide optimal benefit.
Immune modulation in autoimmune disease
The immunomodulatory properties of regenerative therapies also create potential applications in autoimmune disease.
Conditions such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes arise from dysregulated immune responses that target healthy tissue. Conventional therapies, including corticosteroids and biologic agents such as TNF inhibitors, typically act by suppressing specific components of the immune system.
Cell therapies such as MSCs may influence immune signaling through broader regulatory mechanisms. Preclinical and clinical research suggest that MSC therapies can modulate T-cell differentiation, promote regulatory T-cell activity, and influence macrophage polarization toward anti-inflammatory phenotypes.5
These mechanisms suggest regenerative medicine may offer the ability to recalibrate immune signaling networks rather than simply suppress them.
Despite rapid scientific progress, several structural barriers continue to limit the adoption of proactive regenerative medicine strategies in the United States. Healthcare delivery remains largely oriented around late-stage treatment rather than early biological intervention. Reimbursement systems, clinical guidelines, and regulatory reviews all influence when therapies are introduced in the treatment continuum.
Cultural and systemic attitudes toward healthcare also play a role. In many healthcare systems, treatment escalation occurs only after conservative therapies fail and symptoms worsen.
Japan provides an illustrative contrast in certain treatment pathways. For example, intra-articular hyaluronic acid injections are commonly used earlier in the treatment pathway for mild knee osteoarthritis in Japan. In the United States, clinical practice patterns vary widely and often reserve such interventions for later stages of disease progression.
More broadly, the economic case for prevention and early intervention continues to strengthen. Analyses from organizations such as Deloitte suggest that investments in prevention, early detection, and proactive health management could generate substantial long-term savings for healthcare systems. Realizing these benefits will require a structural shift toward earlier detection and earlier therapeutic intervention.
The future of regenerative medicine
The long-term promise of regenerative medicine lies not only in the development of new therapies but in the opportunity to rethink how healthcare approaches chronic disease.
For decades, medical innovation has focused largely on improving treatments for advanced disease. Yet many of the most prevalent conditions—degenerative joint disease, autoimmune disorders, and other chronic inflammatory conditions—are still typically treated only after significant biological damage has already occurred.
Regenerative medicine challenges this model. As our understanding of disease biology deepens, it is becoming increasingly clear that many chronic conditions progress through identifiable biological stages long before irreversible structural damage occurs. Advances in diagnostics, biomarkers, and imaging technologies may soon allow clinicians to detect these signals much earlier than has historically been possible.
When combined with therapies capable of modulating inflammation, immune signaling, and tissue repair, this creates the possibility of intervening earlier in disease progression—preserving function rather than attempting to restore it after it has already been lost.
However, achieving this vision will require more than scientific breakthroughs. Healthcare systems must adapt to support earlier intervention. Regulatory framework standards must continue to evolve to accommodate novel therapeutic modalities. Reimbursement frameworks must recognize the long-term value of disease modification rather than focusing exclusively on late-stage treatment.
Regenerative medicine should not be viewed as a miracle cure. But it represents one of the most promising opportunities to fundamentally change how medicine approaches degenerative disease. If responsibly developed and thoughtfully integrated into healthcare systems, regenerative therapies could help shift medicine toward a more proactive model, i.e., one focused on preserving health, maintaining function, and extending healthy lifespan.
For aging societies around the world, that shift may ultimately prove as important as any single medical breakthrough.
Ed Ahn, MD, is the CEO of Medipost.
References
1. Caplan AI, Correa D. The MSC: An injury drugstore. Cell Stem Cell. 2011;9(1):11–15. doi:10.1016/j.stem.2011.06.008
2. Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. Science. 2019;363(6424):eaaw8730. doi:10.1126/science.aaw8730
3. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. The Lancet. 2019;393(10182):1745–1759. doi:10.1016/S0140-6736(19)30417-9
4. Lim HC, Park YB, Ha CW, Cole BJ, et al. Allogeneic Umbilical Cord Blood–Derived Mesenchymal Stem Cell Implantation Versus Microfracture for Large, Full-Thickness Cartilage Defects in Older Patients: A Multicenter Randomized Clinical Trial and Extended 5-Year Clinical Follow-up. Orthopaedic Journal of Sports Medicine. 2021;9(1):2325967120973052.
5. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Reviews Immunology. 2008;8(9):726–736. doi:10.1038/nri2395
